Araştırma Makalesi
BibTex RIS Kaynak Göster

Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease

Yıl 1993, Cilt: 6 Sayı: 4, 131 - 136, 01.12.1993

S. Hülagü İ. Dinç M. Altın M. Danacı M. Özel Z. Çankır G. Öztürk M. Yaylacı N. Üskent S. Yürütken

Öz

Intensive clinical investigations on Somatostatin have been being carried out in recent years. Somatostatin and its synthetic analogues were initially used in the treatment of endocrine tumors. Today, they are being studied in the treatment of gastrointestinal diseases and successful results are being obtained.

20 chronic liver disease (CLD) patients (10 chronic active hepatitis (CAH) and 10 cirrhosis), and 10 controls were included in this study. Effects of Octreotide on portal venous flow velocity were investigated using Pulsed Doppler technique. All the patients were given 100 meg Octreotide (SC), after the determination of baseline values of blood pressure; pulse rate; blood glucose, urea, creatinin, Na, K and portal venous flow velocity. These criteria were determined again in the 15, 30, 45, 60, 120 and 180th minutes after the injection.

In the patients with CAH, portal venous flow velocity was changed from 11.8+2.6 cm/sec. to 9.9+2.5 cm/sec. in the 15th min. (p<0.01); to 8.7+1.9

cm/sec. in the 30th min. (p<0.01); to 8.6+2.1

cm/sec. in the 45th min. (p<0.01); to 8.7+2.0

cm/sec. in the 60th min. (p<0.01); to 9.0+2.2

cm/sec. in the 120th min. (p<0.05); and to 9.1+2.3 cm/sec. in the180th min. (p<0.05). In the cirrhotic patients and in controls, portal venous flow velocity showed similar changes and we observed that the efficacy of the drug continued until the 180 th minute.

The results of this study revealed that Octreotide had caused reduction in portal venous flow velocity with a rate of 30-35 % in controls, and 20-25 % in patients with CLD.

Anahtar Kelimeler

Octreotide portal hypertension variceal bleeding portal venous flow velocity

Kaynakça

  • Kurtz K. riuesch E.Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986; 21 (Suppl 119) : 65 - 72.

Yıl 1993, Cilt: 6 Sayı: 4, 131 - 136, 01.12.1993

S. Hülagü İ. Dinç M. Altın M. Danacı M. Özel Z. Çankır G. Öztürk M. Yaylacı N. Üskent S. Yürütken

Öz

Kaynakça

  • Kurtz K. riuesch E.Rosenthaler J. Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986; 21 (Suppl 119) : 65 - 72.
Toplam 1 adet kaynakça vardır.

Ayrıntılar

Konular Klinik Tıp Bilimleri
Bölüm Derleme
Yazarlar

S. Hülagü Bu kişi benim

İ. Dinç Bu kişi benim

M. Altın Bu kişi benim

M. Danacı Bu kişi benim

M. Özel Bu kişi benim

Z. Çankır Bu kişi benim

G. Öztürk Bu kişi benim

M. Yaylacı Bu kişi benim

N. Üskent Bu kişi benim

S. Yürütken Bu kişi benim

Yayımlanma Tarihi 1 Aralık 1993
Yayımlandığı Sayı Yıl 1993 Cilt: 6 Sayı: 4

Kaynak Göster

APA Hülagü, S., Dinç, İ., Altın, M., Danacı, M., vd. (1993). Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Medical Journal, 6(4), 131-136.
AMA Hülagü S, Dinç İ, Altın M, Danacı M, Özel M, Çankır Z, Öztürk G, Yaylacı M, Üskent N, Yürütken S. Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Med J. Aralık 1993;6(4):131-136.
Chicago Hülagü, S., İ. Dinç, M. Altın, M. Danacı, M. Özel, Z. Çankır, G. Öztürk, M. Yaylacı, N. Üskent, ve S. Yürütken. “Evaluation of the Effects of Octreotide on Portal Hemodynamics Using Pulsed Doppler Ultrasonography in Patients With Chronic Liver Disease”. Marmara Medical Journal 6, sy. 4 (Aralık 1993): 131-36.
EndNote Hülagü S, Dinç İ, Altın M, Danacı M, Özel M, Çankır Z, Öztürk G, Yaylacı M, Üskent N, Yürütken S (01 Aralık 1993) Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Medical Journal 6 4 131–136.
IEEE S. Hülagü, “Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease”, Marmara Med J, c. 6, sy. 4, ss. 131–136, 1993.
ISNAD Hülagü, S. vd. “Evaluation of the Effects of Octreotide on Portal Hemodynamics Using Pulsed Doppler Ultrasonography in Patients With Chronic Liver Disease”. Marmara Medical Journal 6/4 (Aralık 1993), 131-136.
JAMA Hülagü S, Dinç İ, Altın M, Danacı M, Özel M, Çankır Z, Öztürk G, Yaylacı M, Üskent N, Yürütken S. Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Med J. 1993;6:131–136.
MLA Hülagü, S. vd. “Evaluation of the Effects of Octreotide on Portal Hemodynamics Using Pulsed Doppler Ultrasonography in Patients With Chronic Liver Disease”. Marmara Medical Journal, c. 6, sy. 4, 1993, ss. 131-6.
Vancouver Hülagü S, Dinç İ, Altın M, Danacı M, Özel M, Çankır Z, Öztürk G, Yaylacı M, Üskent N, Yürütken S. Evaluation of the effects of octreotide on portal hemodynamics using pulsed doppler ultrasonography in patients with chronic liver disease. Marmara Med J. 1993;6(4):131-6.